-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: Emerging Companies
2012 BIO International Convention: Q&A with Progenika
In anticipation of the 2012 BIO International Convention we spoke with Progenika, a newly established Spanish healthcare company, to get their perspective on the event. Progenika develops, produces, and commercializes tools for the diagnosis and prognosis of diseases and for predicting response to drug treatment. Read on to learn more about this innovative company. 1) Progenika is a newly established company that has created new subsidiaries; it has internationalized and brought products to the market Read More >
BIO CEO Company Snapshot: NuPathe Inc.
The Company Snapshots have returned for our next One-on-One Partnering event, the BIO CEO & Investor Conference, taking place in New York City this February. The companies that will be profiled in these snapshots will all be presenting at the event, and we hope this provides the opportunity to learn more about them, and catch up on what’s new. For our first Snapshot for the BIO CEO event, we’ve spoken with NuPathe Inc. about their Read More >
Drug Discovery & Development: Partnering for Success…and Survival
There are pressures on Big Pharma and biotech emerging companies alike to engage in more creative deal making to ensure positive outcomes for both parties, Ted Agres writes in Drug Discovery and Development. While the number of deals has remained relatively flat in 2011, the dollar amount of individual deals has increased overall. Oncology remains the most sought after category, followed by CNS, anti-infectives, metabolic diseases, dermatology and cardiovascular. Partnering activity at BIO events is on Read More >
The Critical Importance of International Patent Protection for Small Businesses
As part of the implementation of the Leahy-Smith America Invents Act, the U.S. Patent and Trademark Office (PTO) recently held two public hearing on international patent protection. Stanley C. Erck, President and CEO of Novavax, Inc., testified on behalf of BIO in support of an initiative to reduce filing and prosecution costs for international patent protection of biotech inventions. In his testimony, Mr. Erck explained the important role patents play in the biotechnology industry. The Read More >
State Deficits to Shrink & Taxes Drop – Good News for Biotech
Forecasters at the National Conference of State Legislatures’ 2011 Legislative Summit expect a dramatic reduction of state deficits in the coming years, along with business-friendly tax-cuts. The projections are based on a survey of budget officials in all 50 states last month, said Corina Eckl, director of state services for NCSL. Eckl also noted an emerging trend in which state governors and legislatures are allowing for the expiration of temporary business taxes. Notably, the Michigan Business Read More >
